David Andina Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Andina Martínez has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Jose Antonio Alonso-Cadenas
Pediatric Emergency Department Hospital Infantil Universitario Niño Jesús Madrid Spain
7 shared publications Esther Fernández Mozo
Pediatric Emergency Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
5 shared publications- Antonio Torrelo
Department of Dermatology Hospital Infantil Universitario Niño Jesús Madrid Spain
4 shared publications Jose Antonio Alonso-Cadenas
Pediatric Emergency Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
4 shared publicationsClara Barrueco Ramos
Pediatric Emergency Department, Complexo Hospitalario Universitario de A Coruña , A Coruña, Spain
3 shared publicationsSilvia Escalada Pellitero
Pediatric Emergency Department, Hospital Universitario de Canarias, Tenerife, Spain
3 shared publications
Latest Publications
- 12 November 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (12) , 932
RSV bronchiolitis admissions in infants immunized with nirsevimab: a multicenter observational study
- 12 November 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (12) , 932
RSV bronchiolitis admissions in infants immunized with nirsevimab: a multicenter observational study
- 7 November 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (11)
Decline of RSV Bronchiolitis as the Leading Cause of Hospital Admissions in the Nirsevimab Era
- 7 November 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (11)
Decline of RSV Bronchiolitis as the Leading Cause of Hospital Admissions in the Nirsevimab Era
- Open Access
- 16 July 2026
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 105 (2) , 504259
Evolution of the choice of pediatric places by resident interns during the period 2010–2025
- 16 July 2026
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 105 (2) , 504259
Open AccessEvolution of the choice of pediatric places by resident interns during the period 2010–2025
- Open Access
- 3 June 2026
- Published by Elsevier in Anales de Pediatría
- Vol. 105 (2)
Evolución de la elección de plazas de pediatría por los médicos internos residentes durante el periodo 2010-2025
- 3 June 2026
- Published by Elsevier in Anales de Pediatría
- Vol. 105 (2)
Open AccessEvolución de la elección de plazas de pediatría por los médicos internos residentes durante el periodo 2010-2025
- Open Access
- 19 May 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (9) , 104682
Scabies Cases in Children are Still on the Rise After the COVID-19 Pandemic
- 19 May 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (9) , 104682
Open AccessScabies Cases in Children are Still on the Rise After the COVID-19 Pandemic
- Open Access
- 29 October 2025
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 103 (5) , 504015
In response to the article «Reluctance of parents to immunize their children with nirsevimab»
- 29 October 2025
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 103 (5) , 504015
Open AccessIn response to the article «Reluctance of parents to immunize their children with nirsevimab»
- 14 August 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (8) , e71249
Nirsevimab and Acute Bronchiolitis Admissions in Infants Under One Year of Age
Background and Objectives: Spain was among the first countries to implement universal prophylaxis for respiratory syncytial virus (RSV) using nirsevimab, leading to a 60%–80% reduction in bronchiolitis hospital admissions. The main objective of this study was to describe the characteristics of infants admitted with bronchiolitis after RSV prophylaxis had been established. Methods: A retrospective study was conducted in 15 Spanish pediatric emergency departments during the 2023–2024 RSV season. We reviewed medical records coded as “acute bronchiolitis” of infants aged less than 12 months who were hospitalized. Results: A total of 947 infants with bronchiolitis were included. Of these, 198 (20.9%) were ineligible for immunization because they were older than 6 months and had no comorbidities. Among the 749 (79.1%) infants who met the criteria for immunization, 377 (50.3%) received nirsevimab, of whom 159 (42.1%) tested positive for RSV, while 372 (49.7%) were not immunized, with 322 (86.5%) testing positive for RSV ( p < 0.001). Among infants who were not immunized, the most common reason for not receiving nirsevimab was family refusal. Among infants with RSV bronchiolitis, there were no significant differences in PICU admission rates or length of stay between those who were immunized and those who were not. Conclusion: During the first nirsevimab campaign, most bronchiolitis admissions involved healthy children over 6 months of age who were not included in the target population, eligible infants who were not immunized, and immunized infants with non‐RSV bronchiolitis. Further studies are needed to analyze the characteristics of immunized patients who are admitted with RSV bronchiolitis.
- 14 August 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (8) , e71249
Nirsevimab and Acute Bronchiolitis Admissions in Infants Under One Year of Age
Background and Objectives: Spain was among the first countries to implement universal prophylaxis for respiratory syncytial virus (RSV) using nirsevimab, leading to a 60%–80% reduction in bronchiolitis hospital admissions. The main objective of this study was to describe the characteristics of infants admitted with bronchiolitis after RSV prophylaxis had been established. Methods: A retrospective study was conducted in 15 Spanish pediatric emergency departments during the 2023–2024 RSV season. We reviewed medical records coded as “acute bronchiolitis” of infants aged less than 12 months who were hospitalized. Results: A total of 947 infants with bronchiolitis were included. Of these, 198 (20.9%) were ineligible for immunization because they were older than 6 months and had no comorbidities. Among the 749 (79.1%) infants who met the criteria for immunization, 377 (50.3%) received nirsevimab, of whom 159 (42.1%) tested positive for RSV, while 372 (49.7%) were not immunized, with 322 (86.5%) testing positive for RSV ( p < 0.001). Among infants who were not immunized, the most common reason for not receiving nirsevimab was family refusal. Among infants with RSV bronchiolitis, there were no significant differences in PICU admission rates or length of stay between those who were immunized and those who were not. Conclusion: During the first nirsevimab campaign, most bronchiolitis admissions involved healthy children over 6 months of age who were not included in the target population, eligible infants who were not immunized, and immunized infants with non‐RSV bronchiolitis. Further studies are needed to analyze the characteristics of immunized patients who are admitted with RSV bronchiolitis.
- 2 July 2024
- Published by SEMES (Sociedad Espanola de Medicina de Urgencias y Emergencias) in Emergencias
- Vol. 35 (1) , 31-38
Improving emergency department care of infants with acute bronchiolitis by reducing the use of unrecommended drugs: a quality-of-care initiative in a Spanish autonomous community
Objetivo. Evaluar el impacto de una iniciativa de mejora realizada en los servicios de urgencias (SU) de una comunidad autónoma para reducir el uso de fármacos no recomendados en lactantes con bronquiolitis aguda (BA). Método. Estudio cuasi-experimental analítico del tipo “antes y después de una intervención”. Se incluyeron de forma retrospectiva todas las BA en niños # 12 meses atendidas en los SU de 24 hospitales públicos durante el mes de diciembre de dos periodos epidémicos: 2018 (preintervención) y 2019 (postintervención). Se recogieron variables epidemiológicas, clínicas, asistenciales y evolutivas. La intervención consistió en difundir material informativo y realizar actividades formativas previas al periodo epidémico. Resultados. Se incluyeron 7.717 episodios (2018: 4.007 y 2019: 3.710). No existieron diferencias en las características epidemiológicas y clínicas. El empleo de salbutamol en los SU descendió del 29,4% [intervalo de confianza del 95% (IC 95%): 28,8-30,8] en 2018 al 10,6% (IC 95%: 9,6-11,6) en 2019 (p < 0,001), el de adrenalina del 6,0% (IC 95%: 5,3-6,8) al 0,9% (IC 95%: 0,7-1,3) y el de suero salino hipertónico del 8,2% (IC 95%: 7,3-9,1) al 2,1% (IC 95%: 1,7-2,6) (p < 0,001). La prescripción al alta de salbutamol se redujo del 38,7% (IC 95%: 36,9-40,4) al 10,6% (IC 95%: 9,6-11,6) (p < 0,001). La tasa de ingreso y la tasa de readmisión no cambiaron y la mediana de tiempo de estancia en los SU se redujo 81 minutos [rango intercuartil (RIC) 44-138] a 66 (RIQ: 37-127) (p < 0,001). Conclusiones. La iniciativa de mejora ha conseguido disminuir la tasa de intervenciones terapéuticas no indicadas en BA. Sin embargo, existe una gran variabilidad entre los diferentes SU por lo que la estrategia y la medición de su impacto deben mantenerse en el tiempo.
- 2 July 2024
- Published by SEMES (Sociedad Espanola de Medicina de Urgencias y Emergencias) in Emergencias
- Vol. 35 (1) , 31-38
Improving emergency department care of infants with acute bronchiolitis by reducing the use of unrecommended drugs: a quality-of-care initiative in a Spanish autonomous community
Objetivo. Evaluar el impacto de una iniciativa de mejora realizada en los servicios de urgencias (SU) de una comunidad autónoma para reducir el uso de fármacos no recomendados en lactantes con bronquiolitis aguda (BA). Método. Estudio cuasi-experimental analítico del tipo “antes y después de una intervención”. Se incluyeron de forma retrospectiva todas las BA en niños # 12 meses atendidas en los SU de 24 hospitales públicos durante el mes de diciembre de dos periodos epidémicos: 2018 (preintervención) y 2019 (postintervención). Se recogieron variables epidemiológicas, clínicas, asistenciales y evolutivas. La intervención consistió en difundir material informativo y realizar actividades formativas previas al periodo epidémico. Resultados. Se incluyeron 7.717 episodios (2018: 4.007 y 2019: 3.710). No existieron diferencias en las características epidemiológicas y clínicas. El empleo de salbutamol en los SU descendió del 29,4% [intervalo de confianza del 95% (IC 95%): 28,8-30,8] en 2018 al 10,6% (IC 95%: 9,6-11,6) en 2019 (p < 0,001), el de adrenalina del 6,0% (IC 95%: 5,3-6,8) al 0,9% (IC 95%: 0,7-1,3) y el de suero salino hipertónico del 8,2% (IC 95%: 7,3-9,1) al 2,1% (IC 95%: 1,7-2,6) (p < 0,001). La prescripción al alta de salbutamol se redujo del 38,7% (IC 95%: 36,9-40,4) al 10,6% (IC 95%: 9,6-11,6) (p < 0,001). La tasa de ingreso y la tasa de readmisión no cambiaron y la mediana de tiempo de estancia en los SU se redujo 81 minutos [rango intercuartil (RIC) 44-138] a 66 (RIQ: 37-127) (p < 0,001). Conclusiones. La iniciativa de mejora ha conseguido disminuir la tasa de intervenciones terapéuticas no indicadas en BA. Sin embargo, existe una gran variabilidad entre los diferentes SU por lo que la estrategia y la medición de su impacto deben mantenerse en el tiempo.
- Open Access
- 4 September 2023
- Published by Elsevier in Anales de Pediatría
- Vol. 100 (1) , 57-59
Laringitis agudas en un servicio de urgencias pediátrico antes y después de la pandemia COVID-19. ¿Han cambiado sus características?
- 4 September 2023
- Published by Elsevier in Anales de Pediatría
- Vol. 100 (1) , 57-59
Open AccessLaringitis agudas en un servicio de urgencias pediátrico antes y después de la pandemia COVID-19. ¿Han cambiado sus características?
- 30 September 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (1) , 214-215
Monkeypox disease in a breastfeeding infant
A previously healthy breastfed 7‐month‐old infant presented with several papulovesicular lesions, a hyperemic pharynx and a petechial enanthema. His mother had confirmed monkeypox infection with similar skin lesions on the chest wall. Skin‐to‐skin contact is the most likely mode of transmission of monkeypox. Precautions to limit skin contact during activities such as breastfeeding are recommended if suspected skin lesions are present.
- 30 September 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (1) , 214-215
Monkeypox disease in a breastfeeding infant
A previously healthy breastfed 7‐month‐old infant presented with several papulovesicular lesions, a hyperemic pharynx and a petechial enanthema. His mother had confirmed monkeypox infection with similar skin lesions on the chest wall. Skin‐to‐skin contact is the most likely mode of transmission of monkeypox. Precautions to limit skin contact during activities such as breastfeeding are recommended if suspected skin lesions are present.